Myostatin Inhibitor Peptides
unknown riskAlso: GDF-8 inhibitors · Myostatin propeptide fragments · Anti-myostatin peptides
General reference entry for the class of synthetic peptides designed to inhibit myostatin (GDF-8) — the primary endogenous brake on skeletal muscle growth. Includes propeptide fragments, designed ankyrin repeat proteins (DARPins), and small peptide antagonists. Pipeline compounds from multiple pharma companies at various trial stages.
Reported Benefits
Muscle mass increase
Multiple pipeline compounds show muscle mass increases in animal models. Human data mixed; clinical trials focused on dystrophy and sarcopenia.
Mechanism of Action
Competitive inhibition or decoy receptor binding of myostatin (GDF-8); removes negative feedback on satellite cell activation and muscle protein synthesis.
Pipeline Status
Several myostatin antibodies and peptide inhibitors are in Phase II/III trials for muscular dystrophy (landogrozumab, domagrozumab) and sarcopenia. The peptide-based inhibitors (vs. antibodies) are earlier stage but mechanistically interesting for their potentially superior tissue penetration.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Cardiovascular effects (myostatin has cardiac roles)
- •Reproductive effects
Contraindications
- •Active malignancy
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Myostatin Inhibitor Peptides?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →